Regorafenib targeted drug has certain efficacy on liver cancer, especially for advanced liver cancer or liver cancer that is not able to be operated and has recurred and metastasized, it can play a certain effect of stabilizing and inhibiting the disease. The median overall survival time of regorafenib patients is about 11 months. For patients with advanced hepatocellular carcinoma or those who cannot choose other ways of treatment, they can choose regorafenib for treatment. At the same time, it should be combined with other anti-angiogenic targeted drugs, such as the more widely used PD-1 drugs in clinical practice, which may enhance the survival and reduce the pain of patients with hepatocellular carcinoma when they are combined. However, it should also be noted that regorafenib may also produce side effects, such as impaired liver function, diarrhea, loss of appetite, and even the risk of bleeding from gastrointestinal perforation, and the drug must be taken under the guidance of a doctor.